Novel agent decreases neuropathic pain in patients with type 2 diabetes

Share this content:
Novel agent decreases neuropathic pain in patients with type 2 diabetes
Novel agent decreases neuropathic pain in patients with type 2 diabetes
Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.
READ FULL ARTICLE From Medical Express
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »